GlassScriptPhysician profile
Mobeen N Choudhri
NPI 1942347877
$60,590.51
in general payments reported to CMS, 2019-2025
60 companies · $6,395 in 2025
The $6,395 reported for 2025 was more than what 92% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,862 · 2021: $8,586 · 2022: $6,047 · 2023: $9,347 · 2024: $8,537 · 2025: $6,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Travel and Lodging: $4,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,704.47 |
| Travel and Lodging | $4,575.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17,986.22 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Si-Bone, INC. | $6,665.62 | 2019-2025 | |
| Boston Scientific Corporation | $6,142.51 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Medtronic USA, INC. | $4,433.23 | 2019-2020 | |
| Abbott Laboratories | $4,351.14 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $2,131.99 | 2019-2024 | Senza |
| Saluda Medical Americas, INC. | $2,116.47 | 2023-2025 | Evoke Scs, Evoke |
| Medtronic Vascular, INC. | $1,629.00 | 2019 | |
| Abbvie INC. | $1,340.45 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Relievant Medsystems, INC. | $1,227.51 | 2023 | Intracept |
| Spr Therapeutics, INC | $1,117.15 | 2025 | Sprint Pns System |
| Vertos Medical, INC. | $987.00 | 2021-2024 | Mild Device Kit |
| Teva Pharmaceuticals USA, INC. | $937.25 | 2019-2020 | |
| Biotronik Nro, INC. | $885.72 | 2025 | Prospera |
| Pfizer INC. | $845.93 | 2019-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mobeen Choudhri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.